Bimodal distribution of renal cytochrome P450 3A activity in humans

BD Haehner, JC Gorski, M Vandenbranden, SA Wrighton, SK Janardan, PB Watkins and SD Hall

Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA.

It has been proposed that excessive intrarenal conversion of cortisol to 6 beta-hydroxycortisol by CYP3A may mediate increased tubular reabsorption of sodium, leading to a state of mild volume expansion and the clinical phenotype of salt-sensitive hypertension. Therefore, we characterized CYP3A activity in a bank of microsomes from human kidneys using the formation of 1'-hydroxymidazolam (1'-OHM) as a prototypical CYP3A-catalyzed reaction. Maximal rates of metabolite formation occurred at midazolam concentrations of 12.5-50 microM; higher concentrations resulted in dramatic substrate inhibition. At 12.5 microM midazolam, 4 of 27 kidneys exhibited relatively high mean +/- standard deviation 1'-OHM formation rate (184.0 +/- 14.4 pmol/hr/mg) compared with the remaining 23 samples, which had a mean formation rate of (10.1 +/- 6.4 pmol/hr/mg). Triacetyloleandomycin and anti-CYP3A antibody inhibited midazolam hydroxylation by 53% and 57%, respectively. The correlation between CYP3A5 content, determined through immunoblotting, and 1'-OHM formation rate was high (r2 = 0.84, 24 experiments). The expressions of mRNA corresponding to CYP3A3, CYP3A4, CYP3A5, and CYP3A7 were determined through polymerase chain reaction with specific oligonucleotides as primers. All kidneys examined (25 experiments) expressed CYP3A5 protein and contained the corresponding CYP3A5 mRNA. CYP3A4 mRNA was detected in 40% of the kidney samples, and 70% of those that contained detectable CYP3A4 mRNA also expressed detectable levels of the corresponding protein. Therefore, in contrast to hepatic tissue, in which CYP3A4 is universally expressed, CYP3A5 is the ubiquitously expressed member of the CYP3A family in renal tissue. The distribution of enzyme activity and protein content suggests bimodality and may represent induction of CYP3A5 in a select population and/or a genetically determined organ- specific pattern of expression.

Volume 50, Issue 1, pp. 52-59, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. S. Joy, S. L. Hogan, B. D. Thompson, W. F. Finn, and V. Nickeleit Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1963 - 1968. [Abstract] [Full Text] [PDF]

				C. B. Eap, M. Bochud, R. C. Elston, P. Bovet, M. P. Maillard, J. Nussberger, L. Schild, C. Shamlaye, and M. Burnier CYP3A5 and ABCB1 Genes Influence Blood Pressure and Response to Treatment, and Their Effect Is Modified by Salt Hypertension, May 1, 2007; 49(5): 1007 - 1014. [Abstract] [Full Text] [PDF]

				C. J. O'Donnell, K. Grime, P. Courtney, D. Slee, and R. J. Riley The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting Drug Metab. Dispos., March 1, 2007; 35(3): 381 - 385. [Abstract] [Full Text] [PDF]

				S.-J. Lee, I. P. van der Heiden, J. A. Goldstein, and R. H. N. van Schaik A New CYP3A5 Variant, CYP3A5*11, Is Shown to Be Defective in Nifedipine Metabolism in a Recombinant cDNA Expression System Drug Metab. Dispos., January 1, 2007; 35(1): 67 - 71. [Abstract] [Full Text] [PDF]

				J. S. McCune, L. J. Risler, B. R. Phillips, K. E. Thummel, D. Blough, and D. D. Shen CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION Drug Metab. Dispos., July 1, 2005; 33(7): 1074 - 1081. [Abstract] [Full Text] [PDF]

				H. Ho, A. Pinto, S. D. Hall, D. A. Flockhart, L. Li, T. C. Skaar, P. Cadman, D. T. O'Connor, U. Wagner, N. S. Fineberg, et al. Association Between the CYP3A5 Genotype and Blood Pressure Hypertension, February 1, 2005; 45(2): 294 - 298. [Abstract] [Full Text] [PDF]

				K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]

				H. Zheng, A. Zeevi, E. Schuetz, J. Lamba, K. McCurry, B. P. Griffith, S. Webber, J. Ristich, J. Dauber, A. Iacono, et al. Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism J. Clin. Pharmacol., February 1, 2004; 44(2): 135 - 140. [Abstract] [Full Text] [PDF]

				J. A. Williams, J. Cook, and S. I. Hurst A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5? Drug Metab. Dispos., December 1, 2003; 31(12): 1526 - 1530. [Abstract] [Full Text] [PDF]

				R. C. Givens, Y. S. Lin, A. L. S. Dowling, K. E. Thummel, J. K. Lamba, E. G. Schuetz, P. W. Stewart, and P. B. Watkins CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults J Appl Physiol, September 1, 2003; 95(3): 1297 - 1300. [Abstract] [Full Text] [PDF]

				P.-S. Shih and J.-D. Huang Pharmacokinetics of Midazolam and 1'-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes Drug Metab. Dispos., December 1, 2002; 30(12): 1491 - 1496. [Abstract] [Full Text] [PDF]

				Y. S. Lin, A. L. S. Dowling, S. D. Quigley, F. M. Farin, J. Zhang, J. Lamba, E. G. Schuetz, and K. E. Thummel Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism Mol. Pharmacol., July 1, 2002; 62(1): 162 - 172. [Abstract] [Full Text] [PDF]

				A. Asghar, J. C. Gorski, B. Haehner-Daniels, and S. D. Hall Induction of Multidrug Resistance-1 and Cytochrome P450 mRNAs in Human Mononuclear Cells by Rifampin Drug Metab. Dispos., January 1, 2002; 30(1): 20 - 26. [Abstract] [Full Text] [PDF]

				F.-C. Chou, S.-J. Tzeng, and J.-d. Huang Genetic Polymorphism of Cytochrome P450 3A5 in Chinese Drug Metab. Dispos., September 1, 2001; 29(9): 1205 - 1209. [Abstract] [Full Text] [PDF]

				Y. Lin, P. Lu, C. Tang, Q. Mei, G. Sandig, A. D. Rodrigues, T. H. Rushmore, and M. Shou Substrate Inhibition Kinetics for Cytochrome P450-Catalyzed Reactions Drug Metab. Dispos., April 1, 2001; 29(4): 368 - 374. [Abstract] [Full Text]

				W. Zheng, F. Jin, L. A. Dunning, X.-O. Shu, Q. Dai, W.-Q. Wen, Y.-T. Gao, and J. L. Holtzman Epidemiological Study of Urinary 6{beta}-Hydroxycortisol to Cortisol Ratios and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 237 - 242. [Abstract] [Full Text]

				M. G. Pike, D. C. Mays, D. W. Macomber, and J. J. Lipsky Metabolism of a Disulfiram Metabolite, S-Methyl N,N-Diethyldithiocarbamate, by Flavin Monooxygenase in Human Renal Microsomes Drug Metab. Dispos., February 1, 2001; 29(2): 127 - 132. [Abstract] [Full Text]

				J. M. Lasker, W. B. Chen, I. Wolf, B. P. Bloswick, P. D. Wilson, and P. K. Powell Formation of 20-Hydroxyeicosatetraenoic Acid, a Vasoactive and Natriuretic Eicosanoid, in Human Kidney. ROLE OF CYP4F2 AND CYP4A11 J. Biol. Chem., February 11, 2000; 275(6): 4118 - 4126. [Abstract] [Full Text] [PDF]

				B. J. Ring, S. A. Wrighton, S. L. K. Aldridge, K. Hansen, B. Haehner, and L. A. Shipley Flavin-Containing Monooxygenase-Mediated N-Oxidation of the M1-Muscarinic Agonist Xanomeline Drug Metab. Dispos., October 1, 1999; 27(10): 1099 - 1103. [Abstract] [Full Text]

				A. Honda, G. Salen, Y. Matsuzaki, A. K. Batta, G. Xu, E. Leitersdorf, G. S. Tint, S. K. Erickson, N. Tanaka, and S. Shefer Side Chain Hydroxylations in Bile Acid Biosynthesis Catalyzed by CYP3A Are Markedly Up-regulated in Cyp27-/- Mice but Not in Cerebrotendinous Xanthomatosis J. Biol. Chem., September 7, 2001; 276(37): 34579 - 34585. [Abstract] [Full Text] [PDF]